Topic: commercial manufacturing
Just months after announcing a $65 million expansion to boost capacity and jobs at its North Carolina facility, Novo says it needs more of both.
A Chinese maker of heparin and APIs for oncology and other drugs is investing nearly $150 million as it targets innovative drugs for China.
Sun Pharma is picking up two manufacturing plants and a portfolio of dermatology drugs in Japan for just $1 million.
India's Glenmark is opening a $100 million plant in North Carolina to make generic drugs.
GlaxoSmithKline continues to plow money into upgrading respiratory drug production, with the latest an expansion in Scotland to make APIs for inhalers.
Here is some news of note for the week.
India’s Dr. Reddy’s Laboratories says it will unload an API manufacturing plant to the Middle East-based Neopharma.
Shire’s $1 billion plasma fractionation plant in Georgia has gone through three owners but is now officially open.
Israel-based Teva, whose pledge to unload manufacturing plants in its home country sparked strikes, is reportedly close to selling a site there.
GlaxoSmithKline will keep its cephalosporin antibiotics business but reorganize it to be more efficient, cutting nearly 200 jobs in the U.K.